FDA Shares Biosimilar Progress and Seeks Input at Public Meeting
Published Date: 8/15/2025
Notice
Summary
The FDA is hosting a public meeting to share progress on their Biosimilar User Fee Act III program, which helps speed up the development of biosimilar medicines. This program supports companies making affordable alternatives to brand-name biologic drugs, aiming to make these medicines easier and faster to bring to patients between 2023 and 2027. They’re also asking for ideas on what research to focus on next to keep improving the process.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
FDA pilot speeds biosimilar development
The FDA launched a BsUFA III regulatory science pilot to help speed development of biosimilar medicines and support companies making affordable alternatives to brand-name biologic drugs between 2023 and 2027. The pilot focuses on advancing interchangeable products and improving development efficiency to help firms bring biosimilars to market faster.
Potential faster access to cheaper biologics
The BsUFA III program aims to make biosimilar and interchangeable medicines easier and faster to bring to patients between 2023 and 2027. By advancing interchangeability and improving development efficiency, the program is intended to support availability of more affordable biologic treatment options for patients.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16959, Frequently Asked Questions-Developing Potential Cellular and Gene Therapy Products; Final Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance titled "Frequently asked Questions--Developing Potential Cellular and Gene Therapy Products." The guidance document provides industry with answers to frequently asked questions (FAQs) and commonly faced issues that arise during the development of cellular and gene therapy (CGT) products. The FAQs represent common questions directed to the Agency and span multiple disciplines, including regulatory review; chemistry, manufacturing, and controls (CMC); pharmacology/toxicology; clinical; and clinical pharmacology. This guidance announced in this notice finalizes the draft guidance of the same title issued on November 19, 2024.
2026-16939, GNT USA, LLC.; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by GNT USA, LLC., c/o Exponent, Inc., proposing that we amend our color additive regulations to provide for the safe use of safflower (Carthamus tinctorius L.) extract as a color additive in various foods at levels consistent with good manufacturing practices.
2026-16942, Food Additives Permitted in Feed and Drinking Water of Animals; Chromium DL-methionine Chelate
The Food and Drug Administration (FDA, we, or the Agency) is amending the regulations for food additives permitted in feed and drinking water of animals to provide for the safe use of chromium DL- methionine chelate as a nutritional source of chromium in cattle feed. This action is in response to a food additive petition filed by Zinpro Corp.
Previous / Next Documents
Previous: 2025-15570, NextEra Energy Point Beach, LLC; Point Beach Nuclear Plant, Units 1 and 2; Final Supplemental Environmental Impact Statement
NextEra Energy wants to keep running the Point Beach Nuclear Plant in Wisconsin for 20 more years, and the NRC just finished a big review to make sure it’s safe for people and the environment. This decision affects local communities, energy customers, and the environment, with no major changes to costs or timing announced. The plant’s continued operation means steady power and jobs for years to come!
Next: 2025-15572, Advancing the Development of Interchangeable Products: Identifying Future Needs; Public Workshop; Request for Comments
The FDA is hosting a public workshop to explore how to make interchangeable biosimilar products better and easier to develop. This affects drug makers and patients who want more affordable medicine options. The workshop is part of a plan running through 2027 and aims to gather ideas on future research and guidance, potentially speeding up access and saving money.